Evidence map›Paper›PMID 37925659›Full record

ArticleAnnals of surgical oncology2024

The Effectiveness of Screening Total Colonoscopy for Preoperative Patients with Gastric Cancer.

Yusuke Koseki, Makoto Hikage, Masanori Terashima, Akifumi Notsu, Kenichiro Furukawa, Keiichi Fujiya, Yutaka Tanizawa, Kazunori Takada, Kenichiro Imai, Akio Shiomi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Yusuke KosekiDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Makoto HikageDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan. m.terashima@scchr.jp.ORCID http://orcid.org/0000-0002-2967-8267
Akifumi NotsuClinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Kenichiro FurukawaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Keiichi FujiyaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Yutaka TanizawaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Kazunori TakadaDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Kenichiro ImaiDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Akio ShiomiDivision of Colorectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Etsuro BandoDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is the most common cancer that coincides with gastric cancer (GC). Although the usefulness of total colonoscopy (TCS) as a CRC screening tool has been reported in preoperative patients with GC, the long-term outcome of patients with synchronous CRC (SCRC) remains unclear. This study aims to clarify the significance of preoperative screening TCS for GC in terms of survival outcomes. PATIENTS AND

methodsWe included 796 patients who underwent preoperative screening TCS for GC. The risk factors, clinicopathological features, and survival outcome of SCRC were examined. Furthermore, the cost-effectiveness was evaluated from the perspective of improving the rates of mortality caused by CRC.

resultsSCRC was observed in 43 patients (5.4%). Endoscopic treatment for SCRC was performed on 30 patients. In total, 15 patients underwent surgical resection, including 2 patients requiring additional surgery after endoscopic treatment. Regarding pathological stages, 25 patients had stage 0, 12 patients had stage I, 5 patients had stage II, and 1 patient had stage IIIB disease. The cumulative mortality rates were as follows: GC-related deaths, 12.6%; deaths from cancers other than CRC, 1%; deaths from other causes, 5.5%. No deaths were attributed to SCRC. Comparing the patients who did not undergo TCS, an incremental cost-effectiveness ratio analysis suggested that a screening cost of 5.86 million yen was required to prevent one CRC death.

conclusionsCurative treatment was possible in all patients with SCRC. No deaths were attributed to SCRC, suggesting that screening TCS for GC is effective.

Indexed as

Colorectal NeoplasmsStomach NeoplasmsColonoscopyCost-Benefit AnalysisEarly Detection of CancerHumansMass ScreeningRetrospective StudiesRisk FactorsColorectal cancerCost-effectivenessGastric cancerPreoperative patientsPreoperative screeningTotal colonoscopy

Identifiers

PMID37925659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.